immunologyTariff appliesAnnex III — Jul 31 2026

Dupixent Tariff Rate & July 31, 2026 Deadline

Dupixent (Dupilumab) — manufactured by Regeneron in Ireland. Treats eczema, asthma, nasal polyps. Typical US retail $3,200 per month.

Tariff breakdown

Applicable rate: 100% (Annex III)
Effective date: 2026-07-31 (98 days away)
Manufacturer: Regeneron
Country of origin: Ireland
Annex III?: Yes
Current monthly retail: $3,200

Projected monthly retail, by pass-through scenario

Scenario	Pass-through	New monthly retail	Annual increase
Conservative	30%	$4,160	+$11,520
Likely	50%	$4,800	+$19,200
Worst case	100%	$6,400	+$38,400

Scenarios based on historical brand-pharma cost-shock pass-through. Not a forecast.

HTS classification

HTS 3002.15.0000

Dupilumab is an IL-4/IL-13 receptor antagonist monoclonal antibody, HTS 3002.15. Joint Regeneron/Sanofi product; Ireland manufacturing subject to tariff.

Source: USITC Harmonized Tariff Schedule, 2026 Revision 2 — hts.usitc.gov

Alternatives: generics, biosimilars & US-made options

Xolair (omalizumab, Roche)

therapeutic alternative

Alternative for severe asthma and food allergy; Roche is Annex III and Switzerland-made — tariff applies.

Nucala (mepolizumab, GSK)

therapeutic alternative

Severe eosinophilic asthma alternative; GSK is Annex III, UK-made — tariff applies.

Topical steroids / calcineurin inhibitors

generic

First-line eczema treatments (triamcinolone, tacrolimus) are widely genericized and tariff-exempt.

Always consult your prescriber before switching medications. Biosimilars and generics are not interchangeable in every state without physician approval.

FAQ: Dupixent and the 2026 tariff

Will my Dupixent prescription cost more after July 31, 2026?

Likely yes. Dupixent is manufactured in Ireland and is not exempt. Our conservative-case scenario assumes 30% pass-through (retail +$960/month), our likely-case 50% (+$1,600/month), and worst-case full pass-through (+$3,200/month).

Can I switch to a generic version of Dupilumab?

There are generic options listed above — their availability and interchangeability depend on FDA approval and state substitution rules. Confirm with your pharmacist before switching.

Is Dupixent on the Medicare negotiated-price list?

Dupixent is not among the first-round Medicare-negotiated drugs effective 2026. Check CMS announcements for subsequent negotiation rounds.

Importing pharmaceuticals commercially?

This page covers consumer drug pricing. For business imports (including finished-dose pharmaceuticals), use the full US import tariff calculator with HTS classification and Section 301/232/122 breakdown.

Disclaimer: Informational estimates based on public list prices, the April 2, 2026 Proclamation text, and USITC HTS data. Not medical, legal, or financial advice.

Talk to your doctor, pharmacist, and insurer about your specific medication.